Provided by Tiger Trade Technology Pte. Ltd.

VanEck Biotech ETF

240.47
+6.432.75%
Post-market: 240.14-0.3266-0.14%19:30 EDT
Volume:10.88K
Turnover:2.60M
Market Cap:482.50M
PE:- -
High:240.47
Open:234.08
Low:234.08
Close:234.03
52wk High:246.55
52wk Low:171.63
Shares:2.01M
Float Shares:2.01M
Volume Ratio:0.89
T/O Rate:0.54%
Dividend:0.96
Dividend Rate:0.40%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Analysts’ Top Healthcare Picks: Gilead Sciences (GILD), Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Oct 08

Amgen Stock Forecast: Pipeline Wins Strengthen Growth Story as MariTide Phase 3 Advances

TradingKey
·
Oct 08

Sino Biopharmaceutical Stock Slides 3.3% in Hong Kong

Dow Jones
·
Oct 08

Will Phase 3 Trial Start Change Revolution Medicines (RVMD) Narrative

Simply Wall St.
·
Oct 08

Amgen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 08

Moderna Inc. Stock Rises 4.8%, Outperforms Peers

Dow Jones
·
Oct 08

Vertex to Report Q3 2026 Financial Results, Host Conference Call and Webcast

Reuters
·
Oct 08

NASDAQ Top and Bottom Performing Stocks at About 02:45 P.m. EDT on 2026-10-07

Reuters
·
Oct 08

Amgen Inc Stock (AMGN) Moved Up by 3.06% on Oct 7: A Full Analysis

TradingKey
·
Oct 08

Regeneron Pharma Price Target Raised to $779.00/Share from $758.00 by Morgan Stanley

Dow Jones
·
Oct 07

Amgen is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
Oct 07

Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX)

TIPRANKS
·
Oct 07

Early notable gainers among liquid option names on October 7th

TIPRANKS
·
Oct 07

Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib

GlobeNewswire
·
Oct 07

J.P. Morgan Remains a Buy on Gilead Sciences (GILD)

TIPRANKS
·
Oct 07

Gilead : JP Morgan Raises Target Price to $170 from $160

THOMSON REUTERS
·
Oct 07

Moderna Inc. Stock Slips 7.8%, Underperforms Peers

Dow Jones
·
Oct 07

Amgen’s AMG 513 Obesity Trial Reaches Phase 1 Completion, Adding a New Angle to the Weight-Loss Drug Race

TIPRANKS
·
Oct 07

Cognizant, Gilead Sign 5-Year Tech Extension Covering DevOps, AI Tools

MT Newswires Live
·
Oct 06

Cognizant announces five-year extension of its work with Gilead Sciences

TIPRANKS
·
Oct 06